Table 4.

  Hazard ratios (95% confidence interval)* and P values for risk of cancer and death in patients with kidney transplant according to immunosuppressive treatment group with follow-up censored at 24 months

Variable	Any cancer	Non-melanoma skin cancer	Other cancer	Death
Control group	1.00	1.00	1.00	1.00
Sirolimus group	0.55 (0.32 to 0.94), 0.03	0.37 (0.22 to 0.62), <0.001	1.04 (0.51 to 2.12), 0.92	1.38 (1.14 to 1.66), <0.001
Age†	1.06 (1.04 to 1.09), <0.001	1.08 (1.06 to 1.10), <0.001	1.05 (1.02 to 1.08), 0.001	1.07 (1.05 to 1.08), <0.001
Female sex	0.79 (0.63 to 0.99), 0.04	0.77 (0.49 to 1.18), 0.23	0.78 (0.52 to 1.16), 0.22	0.98 (0.77 to 1.24), 0.84
Time after transplantation to randomization†	1.11 (1.08 to 1.15), <0.001	1.14 (1.08 to 1.21), <0.001	1.02 (0.97 to 1.07), 0.55	0.92 (0.86 to 0.98), 0.01
Location:
North America	1.00	1.00	1.00	1.00
Africa	0.37 (0.19 to 0.71), 0.003	0.34 (0.04 to 2.62), 0.29	0.38 (0.17 to 0.87), 0.02	1.23 (0.73 to 2.24), 0.39
Asia	0.68 (0.43 to 1.06), 0.09	—‡	1.66 (1.09 to 2.52), 0.02	1.63 (0.98 to 2.69), 0.06
Europe	0.52 (0.39 to 0.68), <0.001	0.34 (0.18 to 0.63), <0.001	0.9 (0.63 to 1.28), 0.56	1.10 (0.81 to 1.49), 0.53
Oceania	3.41 (1.99 to 5.83), <0.001	4.23 (2.12 to 8.45), <0.001	1.70 (1.01 to 2.88), 0.047	1.05 (0.52 to 2.12), 0.88
South America	0.45 (0.28 to 0.73), 0.001	0.55 (0.32 to 0.95), 0.03	0.33 (0.12 to 0.89), 0.03	1.32 (0.75 to 2.34), 0.34

*Calculated with Cox proportional hazards model. All models adjusted for trial, age, sex, geographic location of participant, and time after transplantation to randomization.

†Per year.

‡Hazard ratio not estimable; too few events.